Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...

FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical firm with a market capitalization of $119.87 billion, announced today a 2.6% increase in its quarterly cash dividend.

FOSTER CITY, Calif. - Gilead Sciences (NASDAQ:GILD) reported fourth quarter results that topped analyst expectations and provided an optimistic forecast for 2025, sending shares up 3.5% in after-hours ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.6% ...

Gilead Sciences' earnings beat Wall Street expectations driven by a boost in HIV product sales. The biopharmaceutical company posted a fourth quarter profit of $1.78 billion, or $1.42 a share, ...

FOSTER CITY, Calif. — FOSTER CITY, Calif. — Gilead Sciences Inc. (GILD) on Tuesday reported fourth-quarter earnings of $1.78 billion. The Foster City, California-based company said it had net income ...